IPP Bureau
GSK’s Penmenvy approved by FDA to help protect against MenABCWY
By IPP Bureau - February 17, 2025
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
By IPP Bureau - February 17, 2025
No safety signals related to the vaccine candidate were identified
Nectar Life Care launches affordable anti-diabetic range of medicines
By IPP Bureau - February 17, 2025
Offers affordable, high-quality solutions for diabetes care
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
By IPP Bureau - February 15, 2025
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients
By IPP Bureau - February 15, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
By IPP Bureau - February 15, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Bayer files for approval of finerenone in heart failure in Japan
By IPP Bureau - February 15, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
By IPP Bureau - February 14, 2025
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%
By IPP Bureau - February 14, 2025
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
By IPP Bureau - February 14, 2025
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Cupid receives Rs. 13.90 cr order for female condoms from Brazil, South Africa and Angola
By IPP Bureau - February 14, 2025
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy
By IPP Bureau - February 13, 2025
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Johnson & Johnson launches new intraocular lens TECNIS PureSee in India
By IPP Bureau - February 13, 2025
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
By IPP Bureau - February 13, 2025
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Utthunga partners with VindAir to advance smart solutions for pharma industry
By IPP Bureau - February 13, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
